Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HBM Holdings Ltd. ( (HK:2142) ) just unveiled an update.
HBM Holdings Ltd. has announced a new evaluation and license agreement with Umoja Biopharma to develop in vivo CAR-T cell products. This collaboration combines HBM’s proprietary platforms with Umoja’s VivoVec™ technology, potentially enhancing the reach and effectiveness of CAR-T therapies. The agreement includes upfront payments and milestone fees for HBM, while Umoja will handle further development and commercialization, potentially strengthening HBM’s position in the biotechnology sector.
The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is known for its proprietary HCAb Harbour Mice® and NonaCarFx™ platforms, which are used in creating CAR-T cell products.
Average Trading Volume: 9,451,439
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.29B
See more data about 2142 stock on TipRanks’ Stock Analysis page.